Navigation Links
BioMarin Announces Third Quarter 2011 Financial Results
Date:10/27/2011

s activities related to Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2010 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

BIOMARIN PHARMACEUTICAL INC.CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands of U.S. dollars, except share and per share amounts)September 30,
2011December 31,
2010 (1)(Unaudited)ASSETSCurrent assets:Cash and cash equivalents$

71,254$

88,079Short-term investments153,120186,033Accounts receivable, net (allowance for doubtful accounts: $839 and $63, respectively)107,05786,576Inventory115,628109,698Other current assets39,96533,874Total current assets487,024504,260Investment in BioMarin/Genzyme LLC1,1681,082Long-term investments145,640128,171Property, plant and equipment, net266,190221,866Intangible assets, net100,780103,648Goodwill51,54353,364Long-term deferred tax assets229,172236,017Other assets13,55914,215Total assets$

1,295,076$

1,262,623LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities:Accounts payable and accrued liabilities$

83,254$

83,844Total current liabilities83,25483,844Convertible debt348,339377,521Other long-term liabilities88,94484,001Total liabilities520,537545,366Stockholders’ equity:Common stock, $0.001 par value
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin to Present at the UBS Global Life Sciences Conference
2. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
3. BioMarin to Present at the Baird Health Care Conference
4. BioMarin to Present at the Wedbush Life Sciences Conference
5. BioMarin Announces Second Quarter 2011 Financial Results
6. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
7. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
8. BioMarin to Present at the William Blair Growth Stock Conference
9. BioMarin to Present at the Jefferies Global Healthcare Conference
10. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
11. BioMarin Announces First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... SAN DIEGO , Dec. 17, 2014 ... PHIA) and Volcano Corporation (NASDAQ: VOLC ), a ... applications, today announced that they have entered into a definitive ... tender offer to acquire all of the issued and outstanding ... total equity purchase price of USD 1 billion (approx. EUR ...
(Date:12/17/2014)... HOLBROOK, N.Y. , Dec. 17, 2014 /PRNewswire/ ... that The Depository Trust Company (DTC) has made ... the Deposit Chill on the Company,s stock effective ... of Northstar,s common stock for depository and book ... and the Company is now once again fully ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... Jan. 22 Protalix,BioTherapeutics, Inc. (Amex: PLX ... concept results in an animal study conducted as ... is being conducted under the agreement the Company ... the technology transfer,arm of the Hebrew University of ...
... approved to reduce both A1C and LDL cholesterol, ... Inc.,announced that the United States Food and Drug ... glycemic control,(measured as hemoglobin A1C) in adults with ... or insulin, either alone or in,combination with other ...
Cached Medicine Technology:Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study 2Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study 3Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 2Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 3Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 4Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 5Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 6Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 7
(Date:12/21/2014)... AZ (PRWEB) December 21, 2014 Parker ... range of heating, cooling, plumbing and other similar home ... in 2014 with regard to its expert contracting services. ... industry leader that has been serving Arizona for well ... in providing the absolute best in quality customer service ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 SCI ... of the issues and systemic barriers for disabled athletes ... Paratriathlon Champion. Scheidies has a condition called juvenile macular ... He describes how he adapted his athletic ambitions to ... his success in triathlon to pioneer the way for ...
(Date:12/21/2014)... As testosterone therapy lawsuit filings ... blood clots from using testosterone products such as AndroGel ... that the male hormone testosterone may increase the risk ... in the Proceedings of the National Academy of Sciences ... of male rats with naturally occurring colon cancer. Dr. ...
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation hosted their ... offices. The Hope for the Holidays Toy Drive is a ... families during the holiday season. This year, the toy drive ... both offices. This event continues to be successful year after ... store managers and assistant managers came out and not only ...
(Date:12/20/2014)... 2014 BambooIndustry.com is a professional company ... The business has recently shown its new engineered bamboo ... its bamboo flooring models. , BambooIndustry.com’s customers come from ... and more. According to the CEO of the company, ... fast in the past few years, and the demand ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2
... CHERRY HILL, N.J., Aug. 25 Nuvilex, Inc. (OTC Bulletin ... on September 1, 2009. Additionally, regional shareholder meetings will be held ... and Los Angeles on September 18th. Regional shareholder meeting times and ... , "We are very aware of our shareholders, ...
... , , , IRVINE, ... the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion ... by U.S. News & World Report as one of ,America,s ... SET pulse oximetry technology. , , ...
... DALLAS Aug. 25, 2009 Minorities have poorer results ... used to remove plaque from inside the carotid artery, according ... author of the study in the journal Stroke. ... July issue of the journal, found that higher rates of ...
... T. Chu, MD, PhD, associate professor at the University ... professor, Massachusetts Institute of Technology, received the 2009 Julie ... The Ellison Medical Foundation, the grants provide funding of ... in advancing understanding of basic aging and its impact ...
... , , ... Iowa has agreed to pay the United States $4.5 million to resolve ... announced today. , , ... claims to Medicare by having financial relationships with five physicians that violated ...
... ... MyClyns Product, the New Personal Germ Protection Spray , ... Mount Kisco, NY (PRWEB) August 25, 2009 -- ... media agency specializing in national brand OTC health and beauty products, recently signed an ...
Cached Medicine News:Health News:Nuvilex to Issue Positive Shareholder Newsletter 2Health News:Nuvilex to Issue Positive Shareholder Newsletter 3Health News:Nuvilex to Issue Positive Shareholder Newsletter 4Health News:Nuvilex to Issue Positive Shareholder Newsletter 5Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 2Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 3Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 4Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 5Health News:Minorities have poorer results, higher rates of inappropriate surgery to prevent stroke 2Health News:Ellison Medical Foundation awards more than $1 million to mid-career scientists 2Health News:Covenant Medical Center to Pay U.S. $4.5 Million to Resolve False Claims Act Allegations 2Health News:Robin Leedy & Associates Wins Social Media Program For Union Springs Pharmaceuticals 2
The 40D is ideal for pediatric ophthalmoscopy and other examinations requiring expansive fundus visibility. Alternatively, this lens may be used at the slit lamp biomicroscope to provide an extremely...
This excellent mid-power lens provides medium field and magnification, with an ideal diameter for grip andmanipulation in the orbital area....
The 15D provides high magnification along with an optimized working distance from the cornea. With its 4.11x magnification it is also well suited for disc and macular observation....
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
Medicine Products: